These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 23620410

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Absolute quantification of [(11)C]docetaxel kinetics in lung cancer patients using positron emission tomography.
    van der Veldt AA, Lubberink M, Greuter HN, Comans EF, Herder GJ, Yaqub M, Schuit RC, van Lingen A, Rizvi SN, Mooijer MP, Rijnders AY, Windhorst AD, Smit EF, Hendrikse NH, Lammertsma AA.
    Clin Cancer Res; 2011 Jul 15; 17(14):4814-24. PubMed ID: 21750197
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease.
    Bauer M, Langer O, Dal-Bianco P, Karch R, Brunner M, Abrahim A, Lanzenberger R, Hofmann A, Joukhadar C, Carminati P, Ghirardi O, Piovesan P, Forloni G, Corrado ME, Lods N, Dudczak R, Auff E, Kletter K, Müller M.
    Clin Pharmacol Ther; 2006 Sep 15; 80(3):216-27. PubMed ID: 16952488
    [Abstract] [Full Text] [Related]

  • 7. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
    Kotsakis A, Agelaki S, Vardakis N, Stathopoulos G, Vamvakas L, Kalykaki A, Kentepozidis N, Kontopodis E, Sfakiotaki G, Mavroudis D, Georgoulias V.
    Cancer Chemother Pharmacol; 2011 Aug 15; 68(2):415-22. PubMed ID: 21069335
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
    Karayama M, Inui N, Kuroishi S, Yokomura K, Toyoshima M, Shirai T, Masuda M, Yamada T, Yasuda K, Suda T, Chida K.
    Cancer Chemother Pharmacol; 2013 Aug 15; 72(2):445-52. PubMed ID: 23807323
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients?
    Minami H, Ohe Y, Niho S, Goto K, Ohmatsu H, Kubota K, Kakinuma R, Nishiwaki Y, Nokihara H, Sekine I, Saijo N, Hanada K, Ogata H.
    J Clin Oncol; 2004 Jul 15; 22(14):2901-8. PubMed ID: 15254059
    [Abstract] [Full Text] [Related]

  • 12. Open-label, randomized, single-dose, crossover study to evaluate the pharmacokinetics and safety differences between two docetaxel products, CKD-810 and Taxotere injection, in patients with advanced solid cancer.
    Cho EK, Park JY, Lee KH, Song HS, Min YJ, Kim YH, Kang JH.
    Cancer Chemother Pharmacol; 2014 Jan 15; 73(1):9-16. PubMed ID: 24337589
    [Abstract] [Full Text] [Related]

  • 13. High plasma levels and effective lymphatic uptake of docetaxel in an orally available nanotransporter formulation.
    Nassar T, Attili-Qadri S, Harush-Frenkel O, Farber S, Lecht S, Lazarovici P, Benita S.
    Cancer Res; 2011 Apr 15; 71(8):3018-28. PubMed ID: 21363913
    [Abstract] [Full Text] [Related]

  • 14. Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: a feasibility and pharmacokinetic study.
    Fushida S, Kinoshita J, Yagi Y, Funaki H, Kinami S, Ninomiya I, Fujimura T, Nishimura G, Kayahara M, Ohta T.
    Oncol Rep; 2008 May 15; 19(5):1305-10. PubMed ID: 18425392
    [Abstract] [Full Text] [Related]

  • 15. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
    Thomas SM, Ogagan MJ, Freilino ML, Strychor S, Walsh DR, Gooding WE, Grandis JR, Zamboni WC.
    Mol Pharmacol; 2008 Mar 15; 73(3):627-38. PubMed ID: 18025070
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer.
    Tan AR, Yang X, Berman A, Zhai S, Sparreboom A, Parr AL, Chow C, Brahim JS, Steinberg SM, Figg WD, Swain SM.
    Clin Cancer Res; 2004 Aug 01; 10(15):5038-47. PubMed ID: 15297405
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer.
    Ohtsuka T, Nomori H, Ebihara A, Watanabe K, Kaji M, Naruke T, Suemasu K, Uno K.
    Ann Thorac Cardiovasc Surg; 2006 Apr 01; 12(2):89-94. PubMed ID: 16702929
    [Abstract] [Full Text] [Related]

  • 20. Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects.
    Sundstedt A, Celander M, Ohman MW, Forsberg G, Hedlund G.
    Int Immunopharmacol; 2009 Aug 01; 9(9):1063-70. PubMed ID: 19410661
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.